Due to a high load of modelling projects, the rate of submission via the website has been reduced.
For a much higher submission rate, please use the Modelling API.

A0A2I3S4J1 (A0A2I3S4J1_PANTR) Pan troglodytes (Chimpanzee)

WD repeat domain 5 UniProtKBAFDB90v4InterProSTRINGInteractive Modelling

334 aa; Sequence (Fasta) ; 71 identical sequences

Available Structures

151 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
X-ray structure of WDR5 bound to the WDR5 win motif peptide Heteromer
P61964;
10-334
SO4;
Assess
Cyclic peptide binder of the WBM-site of WDR5 Heteromer
P01106; P61964;
23-334
Assess
Modulating Protein-Protein Interactions with Visible Light Peptide Backbone Switches Heteromer
G2XKQ0; P61964;
29-334
K;NA;
Assess
WDR5 and Histone H3 Lysine 4 dimethyl complex at 2.1 angstrom Heteromer
P61964; P68431;
29-334
Assess
WDR5 in complex with influenza NS1 C-terminal tail Heteromer
P03495; P61964;
30-334
17×UNX;
Assess
X-ray structure of WDR5-MLL3 Win motif peptide binary complex Heteromer
P61964; Q8NEZ4;
31-334
Assess
Crystal structure of WDR5 in complex with the WDR5-interacting motif of MLL2 Heteromer
O14686; P61964;
31-334
BTB;SO4;
Assess
X-ray structure of WDR5delta24 bound to the Kaposi's sarcoma herpesvirus LANA win motif peptide Heteromer
P61964; Q9QR71;
31-334
Assess
Crystal structure of the KANSL1-WDR5 complex. Heteromer
P61964; Q7Z3B3;
31-334
GOL;
Assess
X-ray structure of WDR5-SETd1a Win motif peptide binary complex Heteromer
O15047; P61964;
31-334
Assess
Crystal structure of WDR5 in complex with the WDR5-interacting motif of MLL4 Heteromer
P61964; Q9UMN6;
31-334
Assess
Crystal structure of WDR5 in complex with a H3Q5ser peptide Heteromer
P61964; P68431;
31-334
SRO;
Assess
Crystal structure of WDR5 in complex with H3K4me3Q5ser peptide Heteromer
P61964; P68431;
31-334
GOL;EDO;SRO;
Assess
Crystal structure of human WDR5 in complex with monomethyl H3R2 peptide Heteromer
P61964; Q6NXT2;
31-334
GOL;SO4;
Assess
X-ray structure of WDR5-MLL1 Win motif peptide binary complex Heteromer
P61964; Q03164;
31-334
Assess
WDR5 in complex with histone H3Q5his peptide Heteromer
P61964; P68431;
31-334
Assess
Structure of WDR5 bound to MLL1 peptide Heteromer
P61964; Q03164;
31-334
SO4;
Assess
X-ray structure of WDR5-MLL4 Win motif peptide binary complex Heteromer
P61964; Q9UMN6;
31-334
Assess
Crystal structure of WDR5 in complex with the WDR5-interacting motif of SET1A Heteromer
O15047; P61964;
31-334
Assess
X-ray structure of WDR5-SETd1b Win motif peptide binary complex Heteromer
P61964; Q9UPS6;
31-334
Assess
Crystal structure of WDR5 in complex with MYC MbIIIb peptide Heteromer
P01106; P61964;
31-334
TRS;EDO;
Assess
WDR5 in complex with unmodified H3K4 peptide Heteromer
P61964; Q6P823;
31-334
Assess
X-ray structure of WDR5-MLL2 Win motif peptide binary complex Heteromer
O14686; P61964;
31-334
Assess
WDR5 in complex with trimethylated H3K4 peptide Heteromer
P61964; Q6P823;
31-334
Assess
Crystal structure of the KANSL1-WDR5-KANSL2 complex. Heteromer
P61964; Q7Z3B3; Q9H9L4;
31-334
Assess
WDR5 in complex with monomethylated H3K4 peptide Heteromer
P61964; Q6P823;
31-334
Assess
Crystal structure of WDR5 in complex with the WDR5-interacting motif of MLL3 Heteromer
P61964; Q8NEZ4;
31-334
Assess
Crystal structure of WDR5 in complex with the WDR5-interacting motif of SET1B Heteromer
P61964; Q9UPS6;
31-334
Assess
WDR5 and unmodified Histone H3 complex at 2.25 Angstrom Heteromer
P61964; P68431;
31-334
Assess
Structural and biochemical insights into MLL1 core complex assembly and regulation. Heteromer
P61964; Q03164; Q15291;
31-334
Assess
WDR5 IN COMPLEX WITH AN RBBP5 PEPTIDE RECRUITED TO NOVEL SITE Heteromer
P61965; Q8BX09;
31-334
GOL;
Assess
Quaternary Complex of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC Homer Heteromer
P40337; P61964; Q15369; Q15370;
30-333
8KH;
Assess
Crystal structure of WDR5-Mb(S4) monobody complex Heteromer
P61964;
31-334
Assess
Crystal structure of Protac MS33 in complex with the WD repeat-containing protein 5 and pVHL:Elongi… Heteromer
P40337; P61964; Q15369; Q15370;
32-334
SCN;EDO;VKA;GOL;NA;
Assess
Symmetric Dimethylation of H3 Arginine 2 is a Novel Histone Mark that Supports Euchromatin Maintena… Heteromer
P61964; P68431;
32-334
Assess
Crystal structure of Protac MS67 in complex with the WD repeat-containing protein 5 and pVHL:Elongi… Heteromer
P40337; P61964; Q15369; Q15370;
32-334
GOL;X6M;
Assess
WDR5 IN COMPLEX WITH AN RBBP5 PEPTIDE AND HISTONE H3 PEPTIDE Heteromer
P61965; P68433; Q8BX09;
32-334
GOL;
Assess
Crystal structure of WDR5 in complex with the WIN peptide of PDPK1 Heteromer
O15530; P61964;
30-332
Assess
Cryo-EM structure of MLL1 in complex with RbBP5 and WDR5 bound to the nucleosome Heteromer
P02281; P06897; P61964; P62799; P84233; Q03164; Q15291;
32-334
SAH;ZN;
Assess
Cryo-EM structure of MLL1 core complex bound to the nucleosome Heteromer
P02281; P06897; P61964; P62799; P84233; Q03164; Q15291; Q9C005; Q9UBL3;
32-334
SAH;ZN;
Assess
Complex between RbBP5-WDR5 and an H2B-ubiquitinated nucleosome Heteromer
P02281; P02302; P06897; P0CG47; P61964; P62799; Q15291;
32-334
Assess
Complex between MLL1-WRAD and an H2B-ubiquitinated nucleosome Heteromer
B4DIJ7; P02281; P06897; P0CG47; P61964; P62799; P84233; Q15291; Q9C005; Q9UBL3;
32-334
SAH;ZN;
Assess
Cryo-EM structure of MLL1 in complex with RbBP5, WDR5, SET1, and ASH2L bound to the nucleosome (Cla… Heteromer
P02281; P06897; P61964; P62799; P84233; Q03164; Q15291; Q9UBL3;
32-334
Assess
Cryo-EM structure of MLL1-NCP (H3K4M) complex, mode02 Heteromer
P02281; P06897; P61964; P62799; P84233; Q03164; Q15291; Q9UBL3;
32-334
Assess
Cryo-EM structure of MLL1 in complex with RbBP5, WDR5, SET1, and ASH2L bound to the nucleosome (Cla… Heteromer
P02281; P06897; P61964; P62799; P84233; Q03164; Q15291; Q9UBL3;
32-334
Assess
Cryo-EM structure of MLL1 in complex with RbBP5, WDR5, SET1, and ASH2L bound to the nucleosome (Cla… Heteromer
P02281; P06897; P61964; P62799; P84233; Q03164; Q15291; Q9UBL3;
32-334
Assess
Structure of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC with PEG linker (conformation #1) Heteromer
P40337; P61964; Q15369; Q15370;
33-334
15×SCN; 13×EDO;P6G;Q3X;
Assess
Structure of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC with PEG linker (conformation #2) Heteromer
P40337; P61964; Q15369; Q15370;
33-334
SCN;Q3X;EDO;
Assess
Structure of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC with C3 linker Heteromer
P40337; P61964; Q15369; Q15370;
33-334
Q3R;
Assess
Structure of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC with Aryl linker Heteromer
P40337; P61964; Q15369; Q15370;
33-333
10×SCN;Q43;EDO;K;
Assess
Structural basis of WDR5-MLL interaction Heteromer
P61964; Q03164;
33-332
SO4;
Assess
Cryo-EM structure of human MLL3-ubNCP complex (4.0 angstrom) Heteromer
P02281; P06897; P61964; P62799; P62979; P84233; Q15291; Q8NEZ4; Q9UBL3;
33-332
ZN;
Assess
Cryo-EM structure of human MLL1-NCP complex, binding mode2 Heteromer
P02281; P06897; P61964; P62799; P84233; Q03164; Q15291; Q9UBL3;
33-332
SAH;ZN;
Assess
Cryo-EM structure of human MLL1-ubNCP complex (3.2 angstrom) Heteromer
P02281; P06897; P61964; P62799; P62979; P84233; Q03164; Q15291; Q9UBL3;
33-332
SAH;ZN;LYS;GLN;
Assess
Cryo-EM structure of human MLL1-ubNCP complex (4.0 angstrom) Heteromer
P02281; P06897; P61964; P62799; P62979; P84233; Q03164; Q15291; Q9UBL3;
33-332
SAH;ZN;
Assess
Cryo-EM structure of human MLL1-NCP complex, binding mode1 Heteromer
P02281; P06897; P61964; P62799; P84233; Q03164; Q15291; Q9UBL3;
33-332
SAH;ZN;LYS;GLN;
Assess
Cryo-EM structure of MLL1-NCP (H3K4M) complex, mode01 Heteromer
P02281; P06897; P61964; P62799; P84233; Q03164; Q15291; Q9UBL3;
33-332
Assess
Crystal structure of human WD repeat-containing protein 5 in complex with 4-(3,5-dimethoxybenzyl)-9…homo-2-mer24-334
VV3;
Assess
Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC intera…homo-2-mer31-334
QF1;
Assess
Characterization of Peptide Ligands Against WDR5 Isolated Using Phage Display Techniquehomo-2-mer31-334
Assess
WDR5 covalently modified at Y228 by (R)-2-SFhomo-2-mer31-334
XKN;GOL;SO4;CL;
Assess
Structure of wdr5monomer11-334
CL;
Assess
Crystal structure of human WDR5 in complex with (1M)-N-[(3,5-difluoro[1,1'-biphenyl]-4-yl)methyl]-6…monomer22-334
YJR;
Assess
Discovery of fragment-inspired heterocyclic benzenesulfonamides as inhibitors of the WDR5-MYC inter…monomer22-334
QBS;SO4;
Assess
Structure of the cryo-trapped WDR5:CS-VIP8 cocrystal after illumination at 405 nm and 180 Kmonomer22-334
Assess
Structure of WDR5:CS-VIP8 cocrystal after illumination in situmonomer22-334
Assess
Structural characterisation of WDR5:CS-VIP8 interaction in cis state 1monomer22-334
Assess
Structure of WDR5:CS-VIP8 crystal after illumination at 405 nm and room temperaturemonomer23-334
Assess
Discovery and Structure-Based optimization of potent and selective WDR5 inhibitors containing a dih…monomer23-334
Q41;
Assess
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…monomer24-334
Q0Y;
Assess
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…monomer24-334
Q1M;
Assess
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…monomer24-334
Q1J;
Assess
Crystal structure of human WDR5 in complex with compound 9emonomer24-334
5MO;GOL;CL;EDO; 14×UNX;
Assess
WDR5delta23monomer24-334
SO4;
Assess
Crystal structure of human WD repeat domain 5 with compound MM-401monomer24-334
Assess
Displacement of WDR5 from chromatin by a pharmacological WIN site inhibitor with picomolar affinitymonomer28-334
HLP;
Assess
Crystal structure of human WD repeat domain 5 with compound MM-402monomer28-334
Assess
WD repeat-containing protein 5 complexed with 4-(7-((1H-imidazol-1-yl)methyl)-5-(1-methyl-3-(triflu…monomer30-334
BEN;UY9;
Assess
Discovery of fragment-inspired heterocyclic benzenesulfonamides as inhibitors of the WDR5-MYC inter…monomer30-334
QBM;
Assess
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…monomer30-334
DMS;G2V;
Assess
Crystal structure of human WD REPEAT DOMAIN 5 in complex with 2-chloro-4-fluoro-3-methyl-N-[2-(4-me…monomer30-334
IA9;EDO; 24×UNX;
Assess
Discovery of fragment-inspired heterocyclic benzenesulfonamides as inhibitors of the WDR5-MYC inter…monomer30-334
QBP;
Assess
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…monomer30-334
G2D;
Assess
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…monomer30-334
NA;FZM;
Assess
Histone H3 recognition and presentation by the WDR5 module of the MLL1 complexmonomer30-334
Assess
WDR5 bound to 2-(3,5-dimethoxybenzyl)-7-((2-methyl-1H-imidazol-1-yl)methyl)-5-(1-methyl-3-(trifluor…monomer30-334
BEN;M4U;
Assess
WDR5 in complex with a WIN site inhibitormonomer30-334
HHM;SO4;DMS;
Assess
Structural basis for the specific recognition of methylated histone H3 lysine 4 by the WD-40 protei…monomer29-333
Assess
WDR5 in complex with Myc site fragment inhibitormonomer31-334
Q8D;
Assess
WDR5 in complex with Myc site fragment inhibitormonomer31-334
Q8G;
Assess
Crystal structure of human WDR5 in complex with compound 19monomer31-334
6IQ;GOL;EDO;
Assess
Histone H3 recognition and presentation by the WDR5 module of the MLL1 complexmonomer31-334
Assess
Crystal structure of human WDR5 in complex with compound OICR-9429monomer31-334
35Q;UNX;
Assess
Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC intera…monomer31-334
Q8S;
Assess
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…monomer31-334
Q0M;
Assess
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…monomer31-334
Q1P;Q1S;
Assess
Displacement of WDR5 from chromatin by a pharmacological WIN site inhibitor with picomolar affinitymonomer31-334
HLS;SO4;
Assess
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…monomer31-334
Q1G;
Assess
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…monomer31-334
G1Y;DMS;
Assess
WDR5 bound to inhibitor MM-589monomer31-334
9BA;SO4;EDO;
Assess
WDR5delta23 bound to (2-(3-phenylpropyl)-1H-imidazol-4-yl)methanolmonomer31-334
OGY;CL;
Assess
Crystal structure of human WDR5 in complex with symmetric dimethyl-L-argininemonomer31-334
SO4;GOL;2MR;
Assess
WDR5delta23 bound to N-(4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)acetamidemonomer31-334
SO4;OH7;CL;
Assess
Crystal structure of human WDR5 in complex with monomethyl L-argininemonomer31-334
SO4;GOL;NMM;
Assess
Crystal structure of human WDR5 in complex with MR4397monomer31-334
ZHF;EDO;UNX;
Assess
WDR5delta23 bound to N-(4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)benzamidemonomer31-334
OH1;
Assess
Histone H3 recognition and presentation by the WDR5 module of the MLL1 complexmonomer31-334
Assess
Crystal structure of human WDR5 in complex with compound 9hmonomer31-334
5ML;GOL;CL;EDO; 13×UNX;
Assess
Crystal structure of WDR5, WD repeat domain 5 in complex with compound SGC-DS-MT-0345monomer31-334
37F;CL;EDO;UNX;
Assess
Crystal structure of human WDR5 in complex with N-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-3-hydroxy-…monomer31-334
YJN;
Assess
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei…monomer31-334
Q0S;
Assess
Crystal structure of human WD repeat domain 5 with compoundmonomer31-334
0BW;EDO;CL;SO4; 17×UNX;
Assess
Crystal structure of human WDR5 in complex with compound 9omonomer31-334
5MN;EDO; 11×UNX;
Assess
Crystal structure of human WDR5 in complex with compound 9dmonomer31-334
5MQ;EDO;UNX;
Assess
Discovery of Potent Orally Bioavailable WD Repeat Domain 5 (WDR5) Inhibitors Using a Pharmacophore-…monomer31-334
MBU;
Assess
Crystal structure of human WD repeat domain 5 with compoundmonomer31-334
NP7;EDO;UNX;
Assess
Histone H3 recognition and presentation by the WDR5 module of the MLL1 complexmonomer31-334
Assess
Structural basis for the specific recognition of methylated histone H3 lysine 4 by the WD-40 protei…monomer30-333
Assess
WDR5 in complex with a WIN site inhibitormonomer31-334
HH7;DMS;SO4;
Assess
WDR5 in Complex with Dimethylated H3K4 Peptidemonomer31-334
Assess
Crystal structure of human WDR5 in complex with L-argininemonomer31-334
ARG;SO4;GOL;
Assess
WDR5 in complex with MLL Win motif peptidomimeticmonomer31-334
Assess
WDR5delta23 bound to (2-butyl-1H-imidazol-4-yl)methanolmonomer31-334
OHJ;
Assess
Crystal structure of WDR5 mutant (S62A)monomer31-334
Assess
Crystal structure of WDR5 mutant (W330F)monomer31-334
Assess
Structural characterisation of WDR5:CS-VIP8 interaction in cis state 2monomer30-333
Assess
Crystal structure of WDR5 mutant (W330Y)monomer31-334
Assess
Crystal structure of human WD repeat domain 5 with compound MM-102monomer31-334
Assess
Crystal structure of human WD repeat domain 5 with compound MM-101monomer31-334
Assess
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…monomer32-334
HLM;
Assess
Crystal of WDR5 (apo-form)monomer32-334
Assess
WDR5delta32 bound to peptidomimeticmonomer32-334
OK4;SO4;
Assess
WDR5delta32 bound to N-(4-(4-(hydroxymethyl)-1H-imidazol-2-yl)butyl)acrylamidemonomer32-334
OJP;SO4;
Assess
Crystal structure of WDR5/histone H3 complexmonomer32-334
Assess
WDR5delta32 bound to (2-methyl-1H-imidazol-4-yl)methanolmonomer32-334
OHG;SO4;
Assess
Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC intera…monomer32-334
Q8M;
Assess
Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC intera…monomer32-334
Q8P;
Assess
Displacement of WDR5 from chromatin by a pharmacological WIN site inhibitor with picomolar affinitymonomer32-334
HLJ;
Assess
Fine-tuning the stimulation of MLL1 methyltransferase activity by a histone H3 based peptide mimeticmonomer32-334
Assess
WDR5delta32 bound to N-(4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)-2-phenylacetamidemonomer32-334
OJG;SO4;
Assess
WDR5delta32 bound to ethyl 3-(4-(hydroxymethyl)-1H-imidazol-2-yl)propanoatemonomer32-334
OJM;SO4;EDO;
Assess
WDR5delta32 bound to methyl benzyl(4-(4-(hydroxymethyl)-1H-imidazol-2-yl)butyl)carbamatemonomer32-334
SO4;OJJ;
Assess
Crystal structure of human WDR5monomer32-334
Assess
WDR5delta32 bound to benzyl (4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)carbamatemonomer32-334
OHV;SO4;
Assess
WD repeat-containing protein 5 complexed with N-[(3,5-dimethoxyphenyl)methyl]-4'-fluoro-5-{[(2E)-2-…monomer32-334
Q6S;
Assess
Crystal structure of human WDR5 in complex with compound WM662monomer31-333
X8N;GOL;SO4;PGE;
Assess
WDR5delta32 bound to methyl (4-(4-(hydroxymethyl)-1H-imidazol-2-yl)butyl)carbamatemonomer32-334
OGM;SO4;
Assess
WDR5delta32 bound to (2-(3-methoxy-3-phenylpropyl)-1H-imidazol-4-yl)methanolmonomer32-334
OH4;PEG;
Assess
Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin…monomer31-332
G2J;SO4;DMS;
Assess
Modulation of MLL1 Methyltransferase Activitymonomer33-332
7DC;
Assess
Modulation of MLL1 Methyltransferase Activitymonomer33-332
7DU;
Assess

2 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
2gnq.1.Amonomer0.9211-334
100.00
Assess
8iy5.1.Bmonomer0.6846-333
24.46
Assess